Monthly migraine days is the key metric for diagnosis, treatment decisions, and insurance coverage. Here's how to count it accurately and why it matters.
Monthly migraine days, commonly abbreviated as MMD, is the single number that headache specialists, clinical trialists, and insurance reviewers all reach for first. It determines whether you qualify for preventive treatment, how your response to that treatment is measured, and whether your insurer will authorize or continue authorizing the medications that cost thousands of dollars a year. Getting that number right is not a formality; it is the foundation of your entire treatment record.
A monthly migraine day is any calendar day on which you experience a migraine attack that meets the diagnostic criteria established by the International Headache Society (IHS). In practical terms, that means the attack involves at least two of the following pain characteristics, unilateral location, pulsating quality, moderate to severe intensity, aggravation by routine activity, combined with at least one associated symptom such as nausea, vomiting, photophobia, or phonophobia.
Duration alone does not disqualify an attack. An attack that lasts only a few hours still counts as a migraine day if it otherwise meets criteria. A day with mild, non-migrainous head pain does not count, even if it is uncomfortable. What matters is the quality and features of the attack, not its severity on a personal pain scale.
Each calendar day is counted once, regardless of what happens during it. An attack that peaks twice in the same day is still one migraine day. An attack that spans several days produces one migraine day for each calendar day it is active.
These two terms are sometimes used interchangeably in casual conversation, but they mean different things in a clinical context and conflating them causes real problems in documentation.
A headache day is any day with head pain of any kind. That includes tension-type headaches, medication overuse headaches, sinus headaches, and migraine. A migraine day is a headache day that specifically meets migraine diagnostic criteria. Not all headache days are migraine days, though for people with frequent migraine, the distinction can blur.
The reason this matters: chronic migraine is defined as 15 or more headache days per month for more than three months, with at least eight of those days meeting migraine criteria. You need both counts to satisfy that definition. If you only track whether your head hurt, you cannot demonstrate that eight of those days were true migraine days, which is what insurers and neurologists actually need to see.
Several practical scenarios trip people up.
Multi-day attacks. An attack that begins on a Monday and continues through Wednesday counts as three migraine days, one for each calendar day the attack is active. Do not collapse a prolonged attack into a single entry.
Attacks that start at night. If an attack wakes you at 11:30 PM on the 14th and continues into the morning of the 15th, you count both days. The attack began on the 14th, so that is a migraine day. The attack was still active on the 15th, so that is also a migraine day.
Treated attacks that abort early. A migraine that you treat with a triptan within the first 30 minutes, and which resolves quickly, still counts as a migraine day. The response to treatment does not erase the attack from the record.
Month length variation. February has fewer days than March. When calculating a monthly average over time, headache specialty guidance typically recommends using a 28-day or 30-day standardized period for comparisons, rather than raw calendar months. Your neurologist will specify the convention they use.
The American Headache Society and the IHS both recommend prospective daily tracking, logging each day as it happens, rather than trying to reconstruct the past month from memory. Recall bias consistently leads to undercounting, which underrepresents true disease burden.
A baseline MMD is the average number of migraine days per month before any new preventive treatment begins. It is almost always established over three months of prospective tracking, though some protocols use a single run-in month.
The baseline is the denominator in every efficacy calculation. Clinical trials define response as a 50% or greater reduction from baseline. Insurers require the same kind of evidence for treatment continuation: they want to see that your current preventive is producing meaningful reduction from where you started. Without a documented baseline, there is no meaningful "before" to compare against.
This is why establishing a diary or tracking record before starting a new preventive matters practically, not just academically. If your neurologist is considering escalating your treatment, three months of consistent daily logs gives them a defensible baseline to put in your chart and in your prior authorization paperwork.
Neurologists use MMD to categorize migraine frequency and make corresponding treatment decisions.
| Frequency Tier | Approximate MMD | Typical Treatment Implications |
|---|---|---|
| Episodic, low-frequency | 0 to 3 days/month | Acute (rescue) treatment only; preventives generally not indicated |
| Episodic, high-frequency | 4 to 14 days/month | Preventive treatment considered; CGRP therapies often eligible |
| Chronic migraine | 15+ headache days/month (8+ with migraine features) | Preventive treatment indicated; stronger insurance authorization support |
The 4 MMD threshold is significant: most clinical guidelines begin considering preventive therapy at this point, particularly when attacks are disabling or acute medications are being used frequently. The 15-day threshold for chronic migraine unlocks additional treatment options and carries more straightforward insurance coverage in many plans.
Frequency is one factor, along with disability, prior treatment failures, and medication overuse, but MMD is the primary quantitative input to those conversations.
Every CGRP monoclonal antibody approved by the FDA, including erenumab, fremanezumab, galcanezumab, and eptinezumab, was evaluated in placebo-controlled trials that used mean monthly migraine days as the primary efficacy endpoint. Regulatory approval was granted based on statistically significant reductions in MMD from a documented baseline.
This means the standard the FDA used to approve these drugs is the same standard your neurologist and insurer use to evaluate whether they are working for you. The terminology is not arbitrary; it connects directly to the evidence base that justifies these treatments existing.
Insurers use MMD in two distinct stages of coverage decisions.
For initial authorization, most plans require documentation of a minimum frequency, commonly 4 or more MMD, along with prior failures of older preventive medications. Without a documented MMD meeting their threshold, authorization is routinely denied regardless of clinical appropriateness.
For continuation or renewal authorization, insurers typically require evidence that the treatment is working: a meaningful reduction in MMD from the documented baseline. A plan that authorized treatment at a baseline of 12 MMD may require your current MMD to be below 6 to approve renewal. If your records do not show a clearly documented baseline and a tracked improvement, the renewal is at risk even if you are clinically responding well.
This article is educational. Counting conventions and clinical thresholds vary by provider, institution, and insurer policy. Work with your neurologist to confirm how they define and document MMD for your specific treatment record.
The connection between daily tracking and accurate MMD is direct. Every entry you make on a pain-free day, every entry you make during an attack, even a short one, contributes to an MMD count that reflects what is actually happening. That count is what your neurologist uses to make escalation decisions, what gets submitted to your insurer at authorization and renewal, and what determines whether a treatment is working.
If your records are complete and consistent, you walk into every appointment and every insurance review with evidence. If they are not, you are arguing from memory against a system that runs on documentation.
Educational, not medical advice. Migraine Tracker: CGRP Log is a personal tracking tool, not a medical device. It does not diagnose, treat, or provide medical advice. Always talk to your clinician.
A monthly migraine day is any calendar day on which a migraine attack occurs, including days when the attack started the previous night. Most headache specialists count a day as a migraine day if it meets established migraine criteria, regardless of how many hours the attack lasts.
CGRP treatment costs are among the highest in migraine care. This plain-language guide explains why, how insurance works, and how documentation protects your access.
Chronic migraine is defined as ≥15 headache days per month. That number determines your diagnosis, your treatment options, and what your insurer will cover.
Consistent migraine tracking protects your CGRP coverage, prevents costly denials, and cuts wasted appointments. Here is how documentation saves real money.
